Private Profits versus Public Policy : : The Pharmaceutical Industry and the Canadian State / / Joel Lexchin.

• Superior document: Title is part of eBook package: De Gruyter University of Toronto Press Complete eBook-Package 2016
• VerfasserIn: Lexchin, Joel,
• Place / Publishing House: Toronto : : University of Toronto Press, , [2018]; ©2016
• Year of Publication: 2018
• Language: English
• Physical Description: 1 online resource (384 p.) :; 6 figures
• Other title: Frontmatter --; Contents --; List Of Boxes, Figures, And Tables --; Preface --; Abbreviations --; Private Profits Versus Public Policy The Pharmaceutical Industry And The Canadian State --; Introduction: Why Do We Care About The Pharmaceutical Industry In Canada? --; 1.(De)Regulation Through Cooperation --; 2. Biased Testing, Hidden Results, And The Regulation Of Clinical Trials --; 3. Approving New Drugs: Better Or Just More? --; 4. Regulating Promotion Or Licensing Deception? --; 5. Health Canada And Drug Safety: How Safe Are We? --; 6. Is Intellectual Property A Right? --; 7. How Revenue Is Generated: Prices, Volume, Mix, And Overall Spending --; 8. Who Gets The Value From Research And Development? --; 9. Canada, The Pharmaceutical Industry, And Access To Medicines In The Global South --; 10. Courage, My Friends; ’Tis Not Too Late To Build A Better World --; Acknowledgments --; References --; Index
• Format: Mode of access: Internet via World Wide Web.
• ISBN: 9781442619609; 9783110665956
• DOI: 10.3138/9781442619609
• Access: restricted access
• Hierarchical level: Monograph
• Statement of Responsibility: Joel Lexchin.

The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren’t the interests of the public supposed to supersede the pursuit of private profit?In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century. Although the Canadian government is supposed to regulate the industry to serve the needs of public health, waves of deregulatory reforms and intellectual property rights legislation have shifted the balance of power in favour of these companies’ quest for profit. Joel Lexchin offers a series of recommendations to tip the scale back in the public’s favour. This enlightening work is the first book that deals exclusively with the pharmaceutical industry in Canada in over thirty years.